DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer.

DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer.

Future Oncol. 2017 Apr 25;:

Authors: Di Noia V, Basso M, Marsico V, Cerchiaro E, Rossi S, D'Argento E, Strippoli A, Schinzari G, Iezzi R, Cassano A, Barone C

Abstract
AIM: This single institution Phase II study evaluated drug-eluting beads loaded with irinotecan (DEBIRI) plus capecitabine in pretreated patients with colorectal cancer liver metastases.
PATIENTS & METHODS: Forty patients with liver-limited or liver-dominant disease, who have failed at least two previous lines of chemotherapy, underwent either four DEBIRI at 2-week interval or two DEBIRI every 4 weeks for bilobar or single-lobe metastases, respectively. Capecitabine was given at 1000 mg/m(2) twice daily on days 1-14 every 3 weeks.
RESULTS: Seven partial responses and 12 stable diseases were observed, achieving a disease control rate of 47.5%. Median progression-free survival and overall survival resulted 4 and 8 months, respectively. Grade 3 adverse events occurred in 6/40 points (15%) of patients.
CONCLUSION: DEBIRI plus capecitabine is a valid treatment option for heavily pretreated patients with colorectal cancer liver metastases.

PMID: 28440086 [PubMed - as supplied by publisher]

http://ift.tt/2oIU5j8